Conference abstract · 26 Oct 2015
EditorialPublished 27 Mar 2021
Medication in Rheumatoid Arthritis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Drugs type the mainstay of medical aid in rheumatism (RA). 5 main categories of medicine are presently used: analgesics, non-steroidal anti-inflammatories (NSAIDs), glucocorticoids, nonbiologic and biological disease-modifying antirheumatic medication. Current clinical observe tips advocate that clinicians begin biological agents if patients have suboptimal response or intolerant to at least one or 2 ancient sickness modifying agents (DMARDs). Immunosuppressant, sulfasalazine, anti-TNF compound and anti-inflammatory are the usually used DMARDs. Currently, anti-TNF is that the usually used initial line biological worldwide followed by abatacept and it’s typically combined with MTX. There’s some proof that tocilizumab is that the only biological as a monotherapy agent. Rituximab is usually not used as a primary line biological medical aid thanks to issues of safety however still as effective as anti-TNF. The long run knowledge for the newer oral tiny molecule biologics like tofacitinib isn't on the market and thence used solely as a final resort.
Subjects
OrthopaedicsAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 22 Mar 2017
Towards Rheumatoid Arthritis Cure: Optimizing Therapy and Prediction of Relapse after Tapering Medications
Conference abstract · 18 Jul 2018
Biomarkers and Investigations in Rheumatoid Arthritis Do they change medical management?
Conference abstract · 22 May 2017
Effects of a tailored telephone education intervention on medication adherence and disease activity in patients with rheumatoid arthritis: A randomized controlled trial
Conference abstract · 16 Jun 2016
Joint preserving surgery for hallux valgus in rheumatoid arthritis with minimum 2-year follow-up
More from this journal
The newest in Journal of Arthritis.
Article · 12 Mar 2024
Outcome of the Treatment of Symptomatic Osteoarthritis of the Trapeziometacarpal Joint with an Oral Compound Containing Hyaluronic Acid, Chondroitin Sulfate, Hydrolyzed Collagen Type II, and Hydrolyzed Keratin in 40 Patients
Article · 18 Jan 2024
Investigating the Microrheological Properties of Knee Synovial Fluid by Means of the Multiple Tracking Technique
Article · 30 Sep 2023
Ankylosing spondylitis
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Arthritis
- SubjectOrthopaedics
- BylineArticles whose byline prints “Hiroshi Kawaguchi”

